Conference detail

Conference Officer: Hannah Barrs (hannah.barrs@eacr.org)

This conference will focus on the basic mechanisms controlling cancer cell signalling circuits at the transcriptome, proteome and phosphoproteome levels, as well as emerging concepts in cancer cell signalling and cutting-edge, OMICS-based insights.

All cancer tissue phenotypes are initiated by deregulated signalling mechanisms in cancer cells. These mechanisms are the largest target entity for targeted cancer therapies. Recent data also strongly indicate that cancer therapy resistance is initiated by non-genetic signaling rewiring via post-translational regulation of proteins involved in signalling networks and transcriptional gene regulation.

However, despite decades of research, our global understanding of how cancer cell signalling circuits are controlled, and how they determine cancer progression and therapy resistance, is still far from complete. Join us online on 10 and 11 February 2026 to hear the latest science in this area from a panel of global experts.

If you work in this field, submit an abstract before 15 December 2025 for a chance to have your work featured as a Proffered Paper or in a Flash Talk presentation. Register by 19 January 2026 to secure your place as a participant.

Speakers: Melissa Junttila (ORIC Pharmaceuticals, USA) | Janne Lehtiö (Karolinska Institut, Sweden) | Lior Lobel (Bar-Ilan University, Israel) | Arjun Raj (Perelman School of Medicine, USA) | Adrian Saurin (University of Dundee, UK) | Zuzana Storchová (RPTU, Germany) | Andreas Trumpp (HI-STEM, Germany) | Stephan Vagner (Institut Curie, France)

Keywords: cancer research, oncology, cancer cell signalling, cell signalling networks, cell signalling control mechanisms, cancer progression, cancer therapy resistance, post-translational protein regulation, transcriptional gene regulation, transcriptomics, proteomics, phosphoproteomics, kinases and phosphatases, signalling rewiring, signal integration, RNA biology in cancer